

UBS Investment Research

Asian Equity Strategy: India Underweight

Regional Strategy

31 May 2006

www.ubs.com/investmentresearch

Sakthi Siva

Strategist
sakthi.siva@ubs.com
+65-6836 5916

Kin Nang Chik

Associate Strategist
kin-nang.chik@ubs.com
+852-2971 8636

How far from fair value?

■ SENSEX down 20% from high

In our AES of 6 March "India Underweight - how far from bubble type valuations?", we suggested that India was trading about 35% above its historical average on a range of valuation measures. After the 20% fall in the SENSEX from its recent high, we now find India to be trading about 14% above its historical average. We estimate fair value around 8800 on SENSEX.

■ India's PE, P/ BV, DY - about 14% above historical averages

The chart below illustrates that India's historic PE has dropped from 22x at the high to 17x currently - this is 15% above the historical average of 14.7x from 1995. India's P/ BV has dropped from 3.73x at the high to 3.07x currently - which is 21% above the historical average of 2.5x since 1995. India's DY of 1.64% is 8% below the average of 1.76% from 1995 (charts 1-2).


■ Still the most overvalued market in the region

On P/ BV vs ROE relative to the region, the premium has dropped from a high of 40% to 27% currently (chart below on the left). Given the long term growth story - strong domestic demand, high and stable ROE, underleveraged households and low mobile phone penetration - India probably deserves a premium of 15%.

■ Staying Underweight


While the SENSEX historically rallies sharply when EMBI spreads peak, we are staying Underweight until we are closer to fair value.

Countries on P/ BV vs ROE relative to the world



Source: UBS estimates

India historic PE



Source: Datastream, UBS estimates

This report has been prepared by UBS Securities Pte. Ltd

ANALYST CERTIFICATION AND REQUIRED DISCLOSURES BEGIN ON PAGE 5

UBS does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Risks in staying underweight

With the SENSEX falling by about 20% from its recent high of 12620 versus a regional fall of about 11%, we look at whether it is prudent to stay Underweight.


The first risk stems from the fact that valuations have improved on a range of measures:

- Historic PE has dropped from a recent high of 22x to 17x. But this is still some 15% above the historical average of 14.7x since 1995 (see chart on the front cover).
- Historic P/ BV has dropped from a recent high of 3.73x to 3.07x currently (see chart 1 below). However, it is still some 21% above the historical average of 2.5x.
- Historic DY has risen from a low of 1.3% to 1.64% currently (see chart 2 below). But the DY is still some 8% shy of the historical average of 1.76% from 1995.
- **On P/ BV vs ROE relative to the region, the premium has dropped from 40% at the recent high to 27% currently. But it remains the most overvalued market in the region (see chart on the front cover).**

1st risk in staying underweight – valuations have improved


Valuations not yet at fair value on PE, DY, P/ BV or P/ BV vs ROE

Chart 1: India P/ BV



Source: Datastream, UBS estimates

Chart 2: India DY



Source: Datastream, UBS estimates

The second risk in staying underweight stems from a potential peaking in EMBI spreads. While EMBI spreads rose last night from 212bp to 216bp, the Table below illustrates that the SENSEX has on average rallied by almost 44% in the 12 months after such a peak on the last 3 occasions.

2nd risk – SENSEX historically rallied sharply when EMBI spreads peaked

Table 1: Performance of the SENSEX in the 3, 6 and 12 months after the last 3 highs in EMBI spreads

Peak in EMBI	t+3	t+6	t+12
07-May-04	-7.7	4.6	14.3
15-Apr-05	16.4	35.9	84.7
14-Oct-05	13.5	37.0	31.8
Average	7.4	25.9	43.6

Source: Bloomberg, Datastream, UBS estimates

But Table 2 highlights that current valuations on PE, PCF and DY – are about 25% higher than it was during the last 3 episodes when EMBI spreads peaked.

Table 2: Indian valuations currently vs last episodes when EMBI spreads peaked


	Peak in EMBI	PE	PCF	DY
	07-May-04	14.5	6.6	1.6
	15-Apr-05	13.4	7.5	2.1
	14-Oct-05	15.3	9.6	1.8
	Average	14.4	7.9	1.9
	Current	17	11.6	1.64
	% Difference	18.1	46.8	12.8

Source: Datastream, UBS estimates

The third risk in staying underweight is the positive long term growth story. India has good long term growth (again reflected in Q4 FY 2006 GDP growing at 9.3%), high and stable ROE (ROE averages 18%), underleveraged households and low mobile phone penetration. As suggested in previous AES, **we think Indonesia is a more attractive way of playing this theme and Indonesia became the 4th cheapest market on P/ BV vs ROE relative to the region last week** (see our AES of 22 May *EMBI spreads*).


3rd risk – attractive long term growth story

Chart 3: Banking sector credits to GDP vs per capita GDP



Source: CEIC, Datastream, UBS estimates

Chart 4: Mobile phone penetration vs per capita GDP



Source: CEIC, Datastream, UBS estimates

The fourth risk in staying Underweight is domestic liquidity. As highlighted by UBS India Strategist, Manishi Raychaudhuri, in his recent reports (latest is 29 May *India Strategy Update*), there is plenty of cash with domestic fund managers and households' investment in equities is still low.

4th risk – domestic liquidity

The fifth risk in staying Underweight is foreign selling abates. Table 3 highlights that net foreign selling as of 29 May was USD1.6billion. This is already larger than the net foreign selling of US\$841million in October 2005 and about US\$400 million in March and April 2005.

5th risk – foreign selling abates

Despite the net foreign selling in May, year-to-date in 2006 net foreign buying is US\$2.5billion – which represents 24% of all net foreign buying in Emerging Asia. This is on top of net foreign buying of US\$10.55billion in 2005 – which was 32% of net foreign purchases last year.

Table 3: Net foreign buying of Emerging Asian equities

Net foreign buying/selling							
Source:	stock exch.	stock exch.	stock exch.	stock exch.	stock exch.	stock exch.	stock exch.
US\$m	India	Indo	Korea	Philippines	Taiwan	Thailand	EM Asia ex Malay
Jan-05	101	218	717	209	103	1,237	2,585
Feb-05	1,853	69	1,506	51	3,718	822	8,019
Mar-05	1,716	-2,033	-1,988	-54	-753	-263	-3,376
Apr-05	-150	84	-182	-37	-688	-182	-1,154
May-05	-235	-1,898	294	-3	4,424	-76	2,506
Jun-05	1,157	243	101	63	4,574	407	6,546
Jul-05	1,824	211	1,635	-11	1,433	330	5,421
Aug-05	1,161	292	-1,061	36	-333	435	530
Sep-05	1,066	317	-830	36	-366	316	539
Oct-05	-841	583	-2,539	26	-926	-653	-4,351
Nov-05	847	46	138	34	5,706	71	6,842
Dec-05	2,047	128	-1,375	5	7,497	531	8,834
Jan-06	805	231	2,217	40	1,312	1,889	6,494
Feb-06	1,693	74	-445	206	2,182	277	3,987
Mar-06	1,509	211	-603	53	-391	-10	770
Apr-06	130	285	517	51	5,411	485	6,879
May-06	-1,622	69	-4,042	106	-1,090	-863	-7,442
2006 YTD	2,515	870	-2,355	455	7,424	1,778	10,687
2005	10,546	-1,741	-3,584	355	24,389	2,976	32,940
2004	8,430	2,191	11,212	319	8,140	119	30,410
2003	6,595	1,117	12,430	-82	13,542	-634	32,968
2002	751	856	-2,015	-53	517	289	345
2001	2,802	441	6,875	86	8,161	-149	18,216
2000	1,593	86	11,238	-123	5,127	-828	17,093
1999	1,724	1,595	1,197	400	8,261	-65	13,112
1998	-148	526	3,314	264	749	679	5,384
1997	1,569	130	526	-406	-227	1,811	3,404
1996	3,036	1,837	3,933	2,101	2,194	499	13,600

Data upto 29 May 2006

Source: Various stock exchanges, UBS estimates

The key question for investors who are Underweight India is what premium does India deserve in a regional context. The premium on P/ BV vs ROE has dropped from a high of 40% to 27% currently. We estimate that a fair premium is probably 15%. So we are staying Underweight.

India's premium 27% versus our estimate of fair of 15%. So staying Underweight.

■ **Statement of Risk**

The risks in staying Underweight India are many. One, it bounces sharply given that it has fallen the most - down 18% vs the region down 11%. Two, EMBI spreads could be peaking and within Asia it tends to bounce the most when they peak at least on the last 3 occasions. Three, the long term growth story remains positive.

■ **Analyst Certification**

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

Required Disclosures

This report has been prepared by UBS Securities Pte. Ltd, an affiliate of UBS AG (UBS).

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures.

UBS Investment Research: Global Equity Ratings Definitions and Allocations

UBS rating	Definition	UBS rating	Definition	Rating category	Coverage ¹	IB services ²
Buy 1	FSR is > 10% above the MRA, higher degree of predictability	Buy 2	FSR is > 10% above the MRA, lower degree of predictability	Buy	39%	35%
Neutral 1	FSR is between -10% and 10% of the MRA, higher degree of predictability	Neutral 2	FSR is between -10% and 10% of the MRA, lower degree of predictability	Hold/Neutral	50%	33%
Reduce 1	FSR is > 10% below the MRA, higher degree of predictability	Reduce 2	FSR is > 10% below the MRA, lower degree of predictability	Sell	11%	27%

1: Percentage of companies under coverage globally within this rating category.

2: Percentage of companies within this rating category for which investment banking (IB) services were provided within the past 12 months.

Source: UBS; as of 31 March 2006.

KEY DEFINITIONS

Forecast Stock Return (FSR) is defined as expected percentage price appreciation plus gross dividend yield over the next 12 months.

Market Return Assumption (MRA) is defined as the one-year local market interest rate plus 5% (a proxy for the equity risk premium and not a forecast).

Predictability Level The predictability level indicates an analyst's conviction in the FSR. A predictability level of '1' means that the analyst's estimate of FSR is in the middle of a narrower, or smaller, range of possibilities. A predictability level of '2' means that the analyst's estimate of FSR is in the middle of a broader, or larger, range of possibilities.

Under Review (UR) Stocks may be flagged as UR by the analyst, indicating that the stock's price target and/or rating are subject to possible change in the near term, usually in response to an event that may affect the investment case or valuation.

Rating/Return Divergence (RRD) This qualifier is automatically appended to the rating when stock price movement has caused the prevailing rating to differ from that which would be assigned according to the rating system and will be removed when there is no longer a divergence, either through market movement or analyst intervention.

EXCEPTIONS AND SPECIAL CASES

US Closed-End Fund ratings and definitions are: Buy: Higher stability of principal and higher stability of dividends; Neutral: Potential loss of principal, stability of dividend; Reduce: High potential for loss of principal and dividend risk.

UK and European Investment Fund ratings and definitions are: Buy: Positive on factors such as structure, management, performance record, discount; Neutral: Neutral on factors such as structure, management, performance record, discount; Reduce: Negative on factors such as structure, management, performance record, discount.

Core Banding Exceptions (CBE): Exceptions to the standard +/-10% bands may be granted by the Investment Review Committee (IRC). Factors considered by the IRC include the stock's volatility and the credit spread of the respective company's debt. As a result, stocks deemed to be very high or low risk may be subject to higher or lower bands as they relate to the rating. When such exceptions apply, they will be identified in the Companies Mentioned table in the relevant research piece.

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report.

Global Disclaimer

This report has been prepared by UBS Securities Pte. Ltd or an affiliate thereof ("UBS"). In certain countries UBS AG is referred to as UBS SA.

This report is for distribution only under such circumstances as may be permitted by applicable law. It has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. It is published solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. No representation or warranty, either express or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein, except with respect to information concerning UBS AG, its subsidiaries and affiliates, nor is it intended to be a complete statement or summary of the securities, markets or developments referred to in the report. The report should not be regarded by recipients as a substitute for the exercise of their own judgement. Any opinions expressed in this report are subject to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS as a result of using different assumptions and criteria. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. The analyst(s) responsible for the preparation of this report may interact with trading desk personnel, sales personnel and other constituencies for the purpose of gathering, synthesizing and interpreting market information. UBS is under no obligation to update or keep current the information contained herein. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS, into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this report is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues, however, compensation may relate to the revenues of UBS Investment Bank as a whole, of which investment banking, sales and trading are a part.

The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates and other market conditions. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in this report. For investment advice, trade execution or other enquiries, clients should contact their local sales representative. Neither UBS nor any of its affiliates, nor any of UBS' or any of its affiliates, directors, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this report. **Additional information will be made available upon request.**

United Kingdom, Sweden and Netherlands: Except as otherwise specified herein, this material is communicated by UBS Limited, a subsidiary of UBS AG, to persons who are market counterparties or intermediate customers (as detailed in the FSA Rules) and is only available to such persons. The information contained herein does not apply to, and should not be relied upon by, private customers. **France:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities France SA. **Germany:** Prepared by UBS Limited. Distributed by UBS Limited and UBS Deutschland AG. UBS Limited is regulated by FSA. UBS Deutschland AG is regulated by Bundesanstalt für Finanzdienstleistungsaufsicht. **Spain:** Prepared by UBS Limited and distributed by UBS Securities Espana SV SA, a member of the Comision Nacional del Mercado de Valores. **Russia:** Prepared and distributed by the Moscow Representative Office of UBS Cyprus Moscow Limited. **Switzerland:** Distributed by UBS AG to persons who are institutional investors only. **Italy:** Should persons receiving this research in Italy require additional information or wish to effect transactions in the relevant securities, they should contact UBS Italia SIM S.p.A. **South Africa:** UBS South Africa (Pty) Limited is a member of the JSE Limited. UBS South Africa (Pty) Limited is an authorised Financial Services Provider. **United States:** Distributed to US persons by either UBS Securities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a "non-US affiliate"), to major US institutional investors only. UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for the content of a report prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc. All transactions by a US person in the securities mentioned in this report must be effected through UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. **Canada:** Distributed by UBS Securities Canada Inc., a subsidiary of UBS AG and a member of the principal Canadian stock exchanges & CIPF. A statement of its financial condition and a list of its directors and senior officers will be provided upon request. **Hong Kong:** Distributed by UBS Securities Asia Limited. **Singapore:** Distributed by UBS Securities Pte. Ltd or UBS AG, Singapore Branch. **Japan:** Distributed by UBS Securities Japan Ltd to institutional investors only. **Australia:** Distributed by UBS AG (Holder of Australian Financial Services Licence No. 231087) and UBS Securities Australia Ltd (Holder of Australian Financial Services Licence No. 231098) only to "Wholesale" clients as defined by s761G of the Corporations Act 2001. **New Zealand:** Distributed by UBS New Zealand Ltd.

© 2006 UBS. All rights reserved. This report may not be reproduced or redistributed, in whole or in part, without the written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect.

